However, most of these clinical trials were conducted in patients with diabetic nephropathy, and it is unclear to what extent the nephroprotective effect of SGLT2 inhibitors in patients results from a reduction in blood glucose. This evidence concerns the gene SLC5A2 and diabetic kidney disease.